Abstract
Targeted drugs aimed at driver gene, such as Gefitinib, Erlotinib and Crizotinib, have an irreplaceable position in the therapy of advanced non-small cell lung cancer. These drugs bring benefit to patients, however, higher hepatotoxicity is also presented. Now, drug induced hepatotoxicity and its mechanism are reviewed.